**Data source table in the application of BRAT framework in the Wave 1 Case Study Report Natalizumab**

| **GROUP** | **CATEGORY** | **OUTCOME** | **STATISTIC** | **SOURCE** | **DRUG** | **ACTIVE** | **PLACEBO** | **ACTIVE/PLACEBO** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Benefit |   |   |   |   |   | EST | LOW CI |  | EST | LOW CI | UPP CI | EST | LOW CI | UPP CI |
|   | Relapse |   | Annualised relapse rate | Polman 2006 and EPAR | Natalizumab | 0.23 | 0.19 | 0.28 | 0.73 | 0.62 | 0.87 | 0.32 | 0.26 | 0.4 |
|   |   |   |  | Jacobs 1996 | Beta-interferon | 0.67 |  |   | 0.82 |  |  | 0.82 | 0.56 | 1.20 |
|   |   |   |   | Johnson 1998 | Glatiramer acetate | 0.65 |   |   | 0.91 |   |   | 0.71 | 0.47 | 1.08 |
|   | Disability progression |   | 6-month confirmed % progressing after 2 years | EPAR | Natalizumab | 11% |  |   | 23% |  |  |   |  |  |
|   |   |   | 6-month confirmed hazard | Polman 2006 | Natalizumab | 0.078 |  |   | 0.174 |  |  | 0.46 | 0.33 | 0.64 |
|   |   |   | 6-month confirmed % progressing after 2 years | Jacobs 1996 | Beta-interferon | 21.9% |  |   | 34.9% |  |  |   |  |  |
|   |   |   | 6-month confirmed hazard | Jacobs 1996 | Beta-interferon | 0.165 |  |   | 0.286 |  |  | 0.58 | 0.32 | 1.03 |
|   |   |   | 3-month confirmed % progressing after 2 years | Johnson 1995 | Glatiramer acetate | 21.6% |  |   | 24.6% |  |  |   |  |  |
|   |   |   | Ratio between 3-month and 6-month | Kappos 2010 | Glatiramer acetate | 0.71 |  |   | 0.79 |  |  |   |  |  |
|   |   |   | 6-month confirmed % progressing after 2 years | Glatiramer acetate | 15.3% |  |   | 19.4% |  |  |   |  |  |
|   |   |   | 6-month confirmed hazard | Johnson 1995 | Glatiramer acetate | 0.111 |   |   | 0.144 |   |   | 0.77 | 0.41 | 1.46 |
|   |   | Convenience | Route and frequency of administration | Polman 2006 | Natalizumab | iv qm hosp |  |   |  |  |  |   |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon | im qw |  |   |  |  |  |   |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate | sc od |   |   |   |   |   |   |   |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Risk |   |   |   |   |   | n | N | % | n | N | % |   |   |   |
|   | Infection | Reactivation of serious herpes viral infections |  | Polman 2006 | Natalizumab | 0 | 627 | 0 | 0 | 312 | 0% | 1.00 |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon | 0 | 158 | 0 | 0 | 143 | 0% | 1 |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate | 0 | 125 | 0 | 0 | 126 | 0% | 1 |   |   |
|   |   | PML |  | Kappos 2011 | Natalizumab | 5 | 3722 | 0.1510% | 0 | 3722 | 0% |  |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon | 0 | 158 | 0% | 0 | 143 | 0% |  |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate | 0 | 125 | 0% | 0 | 126 | 0% |  |   |   |
|   | Reproduction toxicity | Congential abnormalities |  | Polman 2006 | Natalizumab | 0 | 627 | 0 | 0 | 312 | 0 |  |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon | 0 | 158 | 0 | 0 | 143 | 0 |  |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate | 0 | 125 | 0 | 0 | 126 | 0 |  |   |   |
|   | Liver Toxicity | Transaminases elevation  | ALT >5x ULN | Polman 2006 | Natalizumab | 31 | 627 | 5% | 12 | 312 | 4% | 1.25 |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon | 0 | 158 | 0% | 0 | 143 | 0% | 1 |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate | 0 | 125 | 0% | 0 | 126 | 0% | 1 |   |   |
|   | Neurological | Seizures |  | Polman 2006 | Natalizumab |  | 627 | 0.50% |  | 312 | 0.50% |  |  |  |
|   |   |   |  | FDA | Beta-interferon |  | 158 | 3% |  | 143 | 0% |  |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate |  | 125 | 0% |  | 126 | 0% |  |   |   |
|   | Others | Infusion reactions/injection reactions |  | Polman 2006 | Natalizumab | 148 | 627 | 24% | 55 | 312 | 18% | 1.34 |  |  |
|   |   |   |  | FDA | Beta-interferon | 20 | 158 | 13% | 18 | 143 | 13% | 1.00 |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate |  | 125 | 90% |  | 126 | 59% | 1.53 |   |   |
|   |   | Hypersensitivity Reactions |  | Polman 2006 | Natalizumab | 25 | 627 | 4% | 0 | 312 | 0% |  |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon |  | 158 | 0 |  | 143 | 0 | 1 |  |  |
|   |   |   |   | FDA | Glatiramer acetate | 17 | 563 | 3% | 11 | 564 | 2% | 1.50 |   |   |
|   |   | Flu-like reactions |  | Polman 2006 | Natalizumab |  | 627 | 0% |  | 312 | 0% | 1 |  |  |
|   |   |   |  | Jacobs 1996 | Beta-interferon | 96 | 158 | 61% | 57 | 143 | 40% | 1.52 |  |  |
|   |   |   |   | Johnson 1995 | Glatiramer acetate |  | 125 | 0 |  | 126 | 0% | 1 |   |   |